Taiwan - Delayed Quote TWD

CHC Healthcare Group (4164.TW)

42.30
-1.80
(-4.08%)
At close: 1:30:25 PM GMT+8
Loading Chart for 4164.TW
  • Previous Close 44.10
  • Open 43.80
  • Bid 42.40 x --
  • Ask 42.50 x --
  • Day's Range 42.20 - 44.00
  • 52 Week Range 35.50 - 60.40
  • Volume 1,555,080
  • Avg. Volume 2,442,933
  • Market Cap (intraday) 7.058B
  • Beta (5Y Monthly) 0.37
  • PE Ratio (TTM) 41.47
  • EPS (TTM) 1.02
  • Earnings Date Aug 5, 2025 - Aug 11, 2025
  • Forward Dividend & Yield 2.00 (4.55%)
  • Ex-Dividend Date Jul 10, 2024
  • 1y Target Est 55.00

CHC Healthcare Group, together with its subsidiaries, engages in trading of pharmaceutical products and health food in Taiwan, China, and internationally. The company is also involved in the sale, leasing, installing, and repairing of medical instruments. In addition, it engages in the sale of ophthalmic equipment; irradiation business; sale of drug and health supplements; consulting, elderly residence, and senior fitness services; Long-term care services; and leasing of veterinary medical instruments. CHC Healthcare Group was founded in 1977 and is headquartered in Taipei City, Taiwan.

www.chcg.com

--

Full Time Employees

December 31

Fiscal Year Ends

Recent News: 4164.TW

View More

Performance Overview: 4164.TW

Trailing total returns as of 5/22/2025, which may include dividends or other distributions. Benchmark is TSEC CAPITALIZATION WEIGHTED ST (^TWII) .

YTD Return

4164.TW
1.20%
TSEC CAPITALIZATION WEIGHTED ST (^TWII)
5.92%

1-Year Return

4164.TW
16.20%
TSEC CAPITALIZATION WEIGHTED ST (^TWII)
0.55%

3-Year Return

4164.TW
25.76%
TSEC CAPITALIZATION WEIGHTED ST (^TWII)
34.23%

5-Year Return

4164.TW
35.64%
TSEC CAPITALIZATION WEIGHTED ST (^TWII)
100.45%

Compare To: 4164.TW

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: 4164.TW

View More

Valuation Measures

Annual
As of 5/21/2025
  • Market Cap

    7.36B

  • Enterprise Value

    10.83B

  • Trailing P/E

    43.24

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    1.86

  • Price/Book (mrq)

    1.07

  • Enterprise Value/Revenue

    2.74

  • Enterprise Value/EBITDA

    11.09

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    4.42%

  • Return on Assets (ttm)

    1.18%

  • Return on Equity (ttm)

    2.69%

  • Revenue (ttm)

    3.95B

  • Net Income Avi to Common (ttm)

    174.52M

  • Diluted EPS (ttm)

    1.02

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    1.77B

  • Total Debt/Equity (mrq)

    72.25%

  • Levered Free Cash Flow (ttm)

    -553.08M

Research Analysis: 4164.TW

View More

Company Insights: 4164.TW

Research Reports: 4164.TW

View More

People Also Watch